

PLOS ONE

Peripheral intravenous catheter insertion and use of ultrasound in patients with difficult intravenous access: Patient and practitioner perspectives to inform future implementation strategies.

--Manuscript Draft--

Manuscript Number:	PONE-D-21-22073
Article Type:	Research Article
Full Title:	Peripheral intravenous catheter insertion and use of ultrasound in patients with difficult intravenous access: Patient and practitioner perspectives to inform future implementation strategies.
Short Title:	Patient and practitioner perspectives to inform DIVA health policy.
Corresponding Author:	Jessica Schults University Of Queensland UQCCR: The University of Queensland Centre for Clinical Research Herston, QLD AUSTRALIA
Keywords:	peripheral catheterization; difficult intravenous access; ultrasound; health policy; systems approach
Abstract:	<p>Objective: To understand healthcare worker and patient experience with peripheral intravenous catheter (PIVC) insertion in patients with difficult intravenous access (DIVA) including the use of ultrasound (US).</p> <p>Methods : Descriptive study using 1-on-1 semi-structured interviews conducted between August 2020 and January 2021. Purposeful sampling was used to recruit healthcare practitioners (HCPs) and patients with DIVA who had PIVC experience. Data were analysed using inductive thematic analysis. Interview data were then mapped to the implementation theory Behaviour Change Wheel to inform implementation strategies.</p> <p>Results: In total 78 interviews (13 patients; 65 HCPs) were completed with respondents from metropolitan (60%), regional (25%) and rural/remote (15%) settings across Australia. Thematic analysis revealed 4 major themes: i) Harmful patient experiences persist, with patient insights not leveraged to effect change; ii) 'Escalation' is just a word on the front lines; iii) Heightened risk of insertion failure without resources and training; and iv) Paving the way forward – 'measures need to be in place to prevent failed insertion attempts. Themes were mapped to the behaviour change wheel and implementation strategies developed, these included: staff education, e-health record for DIVA identification, DIVA standard of care and DIVA guidelines to support escalation and ultrasound use.</p> <p>Conclusion(s): DIVA patients continue to have poor healthcare experiences with PIVC insertion. There is poor standardisation of DIVA assessment, escalation, US use and clinician education across hospitals. Quality, safety, and education improvement opportunities exist to improve the patient with DIVA experience and prevent traumatic insertions. We identified a number of implementation strategies to support future ultrasound and DIVA pathway implementation.</p>
Order of Authors:	<p>Jessica Schults</p> <p>Pauline Calleja</p> <p>Eugene Slaughter</p> <p>Rebecca Paterson</p> <p>Claire M Rickard</p> <p>Catriona Booker</p> <p>Nicole Marsh</p> <p>Mary Fenn</p> <p>Jenny Kelly</p>

	Peter J Snelling
	Joshua Byrnes
	Gerben Keijzers
	Marie Cooke
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS ONE for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p> <p>Unfunded studies Enter: <i>The author(s) received no specific funding for this work.</i></p> <p>Funded studies Enter a statement with the following details:</p> <ul style="list-style-type: none"> • Initials of the authors who received each award • Grant numbers awarded to each author • The full name of each funder • URL of each funder website • Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? • NO - Include this sentence at the end of your statement: <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> • YES - Specify the role(s) played. <p>* typeset</p>	<p>This work was supported by the National Health and Medical Research Council (NHMRC) Partnership Project Grant (APP1180193). https://www.nhmrc.gov.au/</p> <p>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
<p>Competing Interests</p> <p>Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any competing interests that</p>	<p>I have read the journal's policy and the authors of this manuscript have the following competing interests:</p> <p>Jessica Schultz reports grants from Becton Dickinson unrelated to the current project. Claire Rickard: discloses that her current or previous employer has received on her behalf: investigator-initiated research grants from BD-Bard, Cardinal Health and Eloquest; and consultancy payments for lectures or opinion from 3M and BD-Bard;</p>

could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

View published research articles from [PLOS ONE](#) for specific examples.

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

Ethics Statement

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

unrelated to current project.

Nicole Marsh: reports that her affiliated universities have received on her behalf, speaker fees from 3M, investigator-initiated research grants from Becton Dickinson, Cardinal Health, Eloquest Healthcare and a consultancy payment from Becton Dickinson for clinical feedback related to peripheral intravenous catheter placement and maintenance (unrelated to the current project).

Marie Cooke: discloses that her previous employer has received on her behalf: investigator-initiated research grants from BD-Bard unrelated to current project. PC, ES, RP, CB, MF, JK, GK, PS, JB, GK have no conflicts of interest to disclose.

Ethical Approval to undertake the study was received from Griffith University Human Research Ethics Committee (GU: 2020/157)

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

Format for specific study types

Human Subject Research (involving human participants and/or tissue)

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

Animal Research (involving vertebrate animals, embryos or tissues)

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

Field Research

Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

Data Availability

Authors are required to make all data

No - some restrictions will apply

underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the

Aggregated thematic analysis data may be made available upon request to the author, however individual transcriptions are not available due to confidentiality.

XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

* typeset

Additional data availability information:

1 **Peripheral intravenous catheter insertion and use of ultrasound in patients with difficult**
2 **intravenous access: Patient and practitioner perspectives to inform future implementation**
3 **strategies.**

4 Jessica A Schults ^{1,2,3,4*}, Pauline Calleja ⁵, Eugene Slaughter ², Rebecca Paterson ^{1,3,4}, Claire M Rickard
5 ^{1,2,3,6,7}, Catriona Booker ^{1,6}, Nicole Marsh ^{1,3,6}, Mary Fenn ^{3,6}, Jenny Kelly ^{5,7}, Peter J Snelling ^{4,8,9,10},
6 Joshua Byrnes ¹¹, Gerben Keijzers ^{8,10,12}, Marie Cooke ³

7

8 *Corresponding author

9 Dr Jessica Schults, Centre for Clinical Research, University of Queensland, Rm 318 Herston Campus,
10 Queensland 4006, Australia. Tel: +61 (0)7 3346 6077; Email: j.schults@uq.edu.au; ORCID: 0000-0002-
11 5406-9519.

12

13 Author Affiliations:

- 14 1. The University of Queensland, School of Nursing, Midwifery and Social Work
- 15 2. Herston Infectious Diseases Institute (HEiDI), Metro North Hospital and Health Service,
16 Brisbane, Australia
- 17 3. School of Nursing and Midwifery, Griffith University, Brisbane, Australia
- 18 4. Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia
- 19 5. Central Queensland University, Cairns, Australia
- 20 6. Nursing and Midwifery Research Centre; Workforce Development and Education Centre, Royal
21 Brisbane and Women's Hospital, Brisbane, Queensland, Australia
- 22 7. Health and Wellbeing Service Group, Townsville Hospital and Health Service, Townsville,
23 Queensland, Australia
- 24 8. Department of Emergency Medicine, Gold Coast University Hospital, Gold Coast, Queensland,
25 Australia
- 26 9. Sonography Innovation and Research (Sonar) Group, Queensland, Australia
- 27 10. School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia

- 28 11. Centre for Applied Health Economics, Griffith University, Brisbane, Australia
- 29 12. Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52

53 **ABSTRACT**

54 **Objective:** To understand healthcare worker and patient experience with peripheral intravenous
55 catheter (PIVC) insertion in patients with difficult intravenous access (DIVA) including the use
56 of ultrasound (US).

57 **Methods:** Descriptive study using 1-on-1 semi-structured interviews conducted between August
58 2020 and January 2021. Purposeful sampling was used to recruit healthcare practitioners (HCPs)
59 and patients with DIVA who had PIVC experience. Data were analysed using inductive thematic
60 analysis. Interview data were then mapped to the implementation theory Behaviour Change
61 Wheel to inform implementation strategies.

62 **Results:** In total 78 interviews (13 patients; 65 HCPs) were completed with respondents from
63 metropolitan (60%), regional (25%) and rural/remote (15%) settings across Australia. Thematic
64 analysis revealed 4 major themes: i) Harmful patient experiences persist, with patient insights
65 not leveraged to effect change; ii) ‘Escalation’ is just a word on the front lines; iii) Heightened
66 risk of insertion failure without resources and training; and iv) Paving the way forward –
67 ‘measures need to be in place to prevent failed insertion attempts. Themes were mapped to the
68 behaviour change wheel and implementation strategies developed, these included: staff
69 education, e-health record for DIVA identification, DIVA standard of care and DIVA guidelines
70 to support escalation and ultrasound use.

71 **Conclusion(s):** DIVA patients continue to have poor healthcare experiences with PIVC
72 insertion. There is poor standardisation of DIVA assessment, escalation, US use and clinician
73 education across hospitals. Quality, safety, and education improvement opportunities exist to
74 improve the patient with DIVA experience and prevent traumatic insertions. We identified a
75 number of implementation strategies to support future ultrasound and DIVA pathway
76 implementation.

77

78

79

80 INTRODUCTION

81 Approximately 90% of hospitalised patients receive a peripheral intravenous catheter (PIVC)

82 (1), yet insertion is challenging, with two thirds of first attempt insertions failing and some

83 patients requiring more than 10 insertion attempts (needlesticks) (2-5) to obtain access.

84 Nationally, Difficult Intravenous Access (DIVA) affects 30-50% of hospitalised patients (6, 7).

85 Patients at highest risk of DIVA typically fall within the age extremes (8, 9), have chronic

86 disease (resultant poor vein quality) (8, 10), invisible and/or non-palpable due to excess adipose

87 tissue (2, 11); or live in rural/remote areas, with limited access to advanced practitioners (12).

88 The consequences of DIVA are significant, with PIVC insertion failure associated with

89 substantial treatment delays (6), increased healthcare costs (13) and significant pain and patient

90 suffering (14, 15). These reasons have most likely been important drivers for the new -

91 Management of PIVCs Clinical Care Standard released by the Australian Commission on Safety

92 and Quality in Health Care, recommending improved monitoring of PIVC outcomes and shared

93 decision making between patients, carers and clinicians (16). While recommendations on PIVC

94 management are urgently needed to augment care(17), much uncertainty persists in relation to

95 shared decision making in the context of DIVA and how the patient experience can inform

96 future guidelines.

97 In Australia, current systems fail to measure health outcomes (18-20) and patient and

98 practitioner experience related to DIVA (Schults et al, AHR under review). Thereby the

99 processes which are associated with better outcomes remain unclear and the patient experience

100 largely overlooked. Preliminary work conducted in paediatrics show this is largely due to a lack

101 of supporting infrastructure such as policy and training. For example, inserters have little

102 training and preparation before being asked to insert PIVCs, with a lack of formalised DIVA

103 pathways to support difficult insertions (17). Further, international guidelines to support
104 ultrasound (US) guided PIVC insertion as the first approach for DIVA patients, (21, 22) are
105 lacking (17, 23-25). Despite there being growing evidence to support ultrasound PIVC insertion
106 as the first approach for DIVA patients (26, 27), implementation in Australia is negligible (28).
107 Implementation is challenging as PIVC insertion is not limited to one tightly defined
108 professional group but rather across professions/specialties. While globally 80% of PIVCs are
109 nurse-inserted, in Australia this is just 20%, with most insertions by junior medical staff (28). As
110 such our current workforce and systems require purposeful adaptation to implement this
111 capacity. As such health services need to consider adopting implementation strategies based on
112 stakeholder needs relevant to the Behaviour Change Wheel to support sustained behaviour
113 change (29).

114 With significant demand for PIVC insertion in the context of DIVA, it is likely patients,
115 and the current workforce will become increasingly vulnerable to the negative consequences of
116 PIVC insertion failure without purposeful adaptation of the system to improve capacity. In this
117 context, the present study aimed to understand the experiences of patients and healthcare
118 practitioners (HCPs) with DIVA and PIVC insertion. As most studies to date have focused on
119 the patient experience (15, 30), we specifically sought to elucidate the challenges HCPs face,
120 including US use, to inform future studies, interventions, and health care policy development. A
121 secondary aim of the study was to understand what factors may assist in the implementation of
122 new DIVA policy and resources, as mapped to the COM-B
123 These objectives informed the following research questions:

- 124 1. What are the current and desired approaches to PIVC insertion in patients with DIVA?
125
- 126 2. What are the barriers/enablers for US use?
127
- 128 3. What resources are required to support the sustainable implementation of a clinical
129 pathway for DIVA patients?

- 128 4. What are the experiences of Australian patients when undergoing simple and difficult
129 PIVC insertion?
- 130 5. What technology and supportive services do Australian patients (patients) want to
131 improve PIVC insertion procedures?
- 132 6. When mapped to the Behaviour Change Wheel, how do respondents' experiences with
133 DIVA inform future US implementation strategies?

134

135 **METHODS**

136 **Design and Setting**

137 A descriptive qualitative study was undertaken at healthcare facilities across Australia from 5th
138 August 2020 to 15th January 2021. We adopted a naturalist philosophy (31) which is concerned
139 with studying something in its natural state rather than applying a specific theoretical
140 perspective. This approach allowed us to develop a more thorough understanding of participants'
141 DIVA experiences, and has been adopted in contemporary, qualitative, health service research
142 (32). Ethical approval to conduct the study was obtained from Griffith University Human
143 Research Ethics Committee (GU: 2020/157). Participants provided written, informed consent
144 and were able to terminate the interview at any time. Results are reported in line with the
145 Consolidated criteria for reporting qualitative research (COREQ) guidance (33).

146 **Recruitment and characteristics of participants**

147 Participants were HCPs responsible for inserting PIVCs across many Australian patient
148 populations and contexts, and patients who had experience with DIVA. We used purposeful
149 sampling (34) and snowballing, to achieve a balanced sample of HCPs with respect to location
150 and discipline. An email seeking study participation was distributed to the research group's
151 professional organisations (e.g., Australian Vascular Access Society; Council of Remote Area
152 Nurses of Australia, Australian College of Nursing). The lead investigators then approached

153 individual HCPs via email or telephone with a standardised script explaining the details of this
154 voluntary study. To ensure even more perspectives, investigators wrote to a few health services
155 that represented additional geographic diversity and whose workers had not yet been included in
156 the sample. Patients who experienced or whose child experienced difficult PIVC insertion were
157 recruited through invitations to participate via social, radio, online and paper media (e.g.,
158 Queensland Country Life (newspaper); Healthcare Awareness Society of Australia [Facebook
159 site], ABC radio interviews, CQ University online news), with additional invitations sent to
160 healthcare patient groups via email. Due to the broad dissemination strategy (used to minimise
161 coverage and sampling error (35)) we were not able to calculate a denominator and subsequent
162 response rate.

163 **Data collection - semi structured interviews**

164 Three interviewers (two research nurses [MF and JK] and one investigator [JS]) received one-
165 on-one training on interview methods and DIVA (derived from existing literature reviews and
166 quality activities (10, 17)) to carry out in-depth interviews across the vast geographical settings.
167 Experienced moderators (MC and PC) facilitated the training and oversaw the in-depth interview
168 process. The interview guide was informed by prior research conducted by members of the team
169 (15, 17, 20, 28, 36) informal discussions with agency leaders, prior studies on DIVA(10, 37) and
170 PIVC outcomes (38-40). Interview questions broadly focused on participants' lived experience
171 with DIVA (supplementary material 1) and included open-ended questioning. Follow-up
172 prompts were designed to lead participants to recount their personal experience with the DIVA
173 and could be adapted based on participant responses during the interview, allowing a more
174 individualised approach (41). Interviews took place in person, or via telephone due to COVID-
175 19 restrictions on the geographical spread of responding participants. Participant characteristics
176 were noted, as well as the interview setting and conditions, while the interviewer introduced
177 themselves as a clinician researcher working in the field of vascular access. All interviews were

178 audio recorded, with recordings professionally transcribed verbatim for accuracy (42).

179 Interviews lasted approximately 30 minutes; we did not collect non-verbal data.

180 Sample size was not defined a priori as we applied the principle of data saturation, where
181 no new themes emerged from interviews (43, 44). Data saturation was determined using field
182 notes taken by the interviewer detailing a summary of the salient points of the interview. The
183 interviewer then summarised the ‘perceived’ salient points and presented these back to the study
184 participant (on the same day for agreement) to enhance the reliability of study findings. Salient
185 points were then collated contemporaneously to ensure that data saturation was apparent across
186 the multiple interviewers and participants.

187 **Data Analysis**

188 Inductive thematic analysis was used to detail participants’ experiences. HCP and patient data
189 were analysed separately. Analysis was undertaken as per Braun and Clarke’s six phases of
190 thematic analysis (45). Initially three researchers (MC, JS, PC) read transcribed interviews and
191 independently generated initial codes. Line-by-line coding was used (facilitating an audit trail) to
192 enhance dependability (46). Codes were then used to inform concept formation, and themes and
193 sub-themes identified by consensus between researchers. Themes were reviewed in relation to
194 coded extracts and a thematic map generated (led by MC). A selection of extract examples is
195 provided in text to support final themes. Themes were reviewed and defined with continued
196 reference to codes and raw data via discussion with the project team to enhance authenticity
197 (47). A number of strategies were used to enhance data quality and increase rigour, including
198 data immersion and triangulation of emerging findings between researchers (48).

199 Interview themes were mapped to the *Behaviour Change Wheel* (29) by the senior
200 investigator (MC) and cross checked by a second investigator (JS). This implementation theory
201 considers three **sources** of behaviour, **Capability** (*psychological and/or physical*), **Opportunity**
202 (*social and/or physical*), and **Motivation** (*autonomic and/or reflexive*) – *COM-B* (29). These

203 interact to influence and are influenced by behaviour. Interventions can be designed to address
 204 COM-B deficits across all components and as such are multi-faceted. For DIVA PIVC
 205 ultrasound implementation, e.g. *physical capability* requires new ultrasound skills, *psychological*
 206 *capability* requires new thought processes to identify DIVA status, *physical opportunity*
 207 demands available machines, *social opportunity* requires cultural change that resists repeated
 208 landmark attempts, *reflective motivation* may involve internal goalsetting for first attempt
 209 success rate, and *automatic motivation* may require belief that ultrasound can achieve first
 210 attempt success.

211 **RESULTS**

212 In total, 78 participants (65 HCPs and 13 patients) across seven Australian states and territories
 213 participated (Table 1). HCP participants were medical (n = 22; 34%) and nursing (n = 43; 66%)
 214 staff working in diverse health care settings from metropolitan facilities (60%) to rural and
 215 remote locations (15%). Thematic analysis identified 4 major themes with associated subthemes
 216 (Table 2). Theme 1 is representative of patients' current experiences with PIVC insertion.
 217 Themes 2-4 describe HCPs' experience within this clinical context.

218

219 **Table 1. Summary of participant characteristics (N = 78)**

Participant characteristic	Healthcare Practitioner N = 65 (%)	Consumer N = 13 (%)
Gender		
Female	37 (57)	12 (92)
Male	28 (43)	1 (8)
State or Territory		
Queensland	28 (43)	10 (77)
New South Wales	21 (32)	2 (15)
Victoria	6 (9)	0
South Australia	6 (9)	0
Western Australia	2 (3)	0
Northern Territory	1 (2)	0
Tasmania	1 (2)	1 (8)

RRMA Classification			
	Metropolitan	39 (60)	6 (46)
	Regional	16 (25)	5 (39)
	Rural/remote	10 (15)	2 (15)
Speciality			
	Nursing and midwifery ^a	43 (66)	
	<i>Nurse practitioner</i>	6 (14)	
	<i>Nurse</i>	35 (81)	
	<i>Midwife</i>	2 (5)	
	Medical ^a	22 (34)	
	<i>Resident</i>	5 (23)	
	<i>Registrar</i>	2 (9)	
	<i>Consultant</i>	15 (68)	
Patient population			
	Adults	40 (63)	
	Mixed	17 (27)	
	Paediatrics	2 (3)	
	Neonates	4 (6)	
	Paediatrics & neonates	1 (2)	

220 ➤ RRMA: Rural, Remote and Metropolitan Area classification; ^a = total.

221

222

Table 2. Themes and subthemes summarising healthcare practitioners and consumers experiences with DIVA

Theme 1: Harmful patient experiences persist, with consumer insights not leveraged to effect change

Subthemes

- Feeling invisible
- Risk and anticipation of failed PIVC attempts
- Inflexible processes which don't consider patients' needs

Theme 2: 'Escalation' is just a word on the front lines.

Subthemes

- Providing day-to-day care for DIVA patients
- Reliance on 'have a go' culture
- Forced to insert PIVCs in an environment lacking resources and support.

Theme 3: Heightened risk of insertion failure without resources and training.

Subthemes

- Awareness of the benefit of a DIVA pathway
- Education and equipment to support a skilled workforce
- Inserter role and accreditation clarity

Theme 4: Theme 4: Paving the way forward – ‘measures need to be in place to prevent failed insertion attempts’.

Subthemes

- System approach including protocols
- DIVA identification processes

223

224 Theme 1: Harmful patient experiences persist, with patient insights not leveraged to effect 225 change

226 Patients explained that DIVA insertion disrupted their routine medical treatment and day-to-day
227 life. Reporting the extent and severity of failed PIVC insertions as ‘common’ yet ‘horrendous’,
228 with multiple patients recalling feeling ‘ignored’ or ‘dismissed’ when they identified as having
229 ‘DIVA’. Participants also reported feeling like a ‘bad patient’ when they requested an experienced
230 inserter to avoid multiple insertion attempts, and that there was a lack of access to experienced
231 inserters or technology (e.g. US), and were uncertain how to escalate this concern.

232 *‘Horrendous. Yeah. I’ve got a chronic disease, which means I go to hospital*
233 *frequently, both in the public and the private system. Getting someone who is*
234 *an expert to put a drip in is an absolute debacle’ [RRC2’].*

235 Consequences of repeat insertion attempts were reported to include *scarring, apprehension - fear*
236 *of next insertion, distress, pain and bruising*. For patients in rural and remote settings, extreme
237 coping strategies were discussed with one participant reporting

238 *‘When I was younger, I had a lot more issues with cannulations. I would have*
239 *nurses that would attempt three - even like four or five times to cannulate myself*
240 *before they would get it... since then, I’ve learned to cannulate myself’ [RRC1].*

241

242 In addition to worrying about their medical condition, patients also reported feelings of
243 avoidance due to fear of subsequent IV insertions '*I will do anything to avoid going to the*
244 *Emergency Department*' and when hospital admission was unavoidable participants reported
245 '*withdrawing mentally during cannulation as a coping mechanism for pain and discomfort*
246 *caused by failed insertion attempts*' [RRC1]. Finally, patients discussed the need for a '*national*
247 *body to support change in local policy and training*'.

248

249 **Theme 2: 'Escalation is just a word' on the front lines.**

250 HCPs reported that disruptions to medical care from failed insertion attempts were common in
251 hospital settings. Participants discussed varied support and processes for the recognition and
252 assessment of DIVA from (most commonly) no formal process to the use of PIVC insertion
253 policies and finally DIVA decision-making tools. One HCP described the lack of policies meant
254 the '*The intern ... has a few goes and then comes to find me and gets me to do it (experienced*
255 *inserter)*' [RI2A]. In facilities that had policies to support PIVC insertion in patients with DIVA,
256 participants suggested this was largely '*ignored*' with recommendations such as '*two attempts*'
257 then escalate equating to multiple inserters having two attempts before escalating to an advanced
258 inserter '*it's common for 6 to 8 insertion attempts to be made on neonates before escalating*'.
259 Participants described a reliance on alternative sources for support when DIVA policies were not
260 in place. The consequences of failed insertion attempts concerned HCPs who described feelings
261 of distress and stress when they were unable to cannulate '*A cannula being delayed for several*
262 *hours might indicate that a patient doesn't get their antibiotics for an infection for many hours*
263 *and that's more detrimental to the patient*' [R13A].

264

265 In metropolitan hospitals, escalation after hours was most frequently to anaesthetics and this
266 often resulted in further delay because of competing priorities for the anaesthetists.
267 Unsurprisingly, escalation in regional and remote settings was discussed as more challenging,
268 with limited access to technology such as US and advanced inserters e.g., anaesthetists. HCPs
269 from remote locations reported '*try(ing) their best and hope(ing) for the best*'. Consequences of
270 failed insertion attempts included escalation to interosseous device insertion or transfer to a
271 larger healthcare facility which may have meant hours in transit and contributed to significant
272 treatment delays. Owing to the lack of formal processes and training, participants discussed the
273 current '*have a go*' culture and the subsequent delay if escalated to a more experienced
274 colleague due to staffing availability. This was further complicated by HCPs who perceived a
275 difficult balance between the need for junior doctors to learn important cannulation skills and
276 limiting insertion attempts by escalation to someone more experienced.

277

278 **Theme 3: Heightened risk of insertion failure without resources and training.**

279 In general, HCPs believed that '*PIVC insertion in DIVA patients should be attempted by the*
280 *most experienced ... clinician first*' or a DIVA team to prevent multiple insertion attempts. HCP
281 participants also described a lack of uncertainty regarding '*whose role it is*' to insert PIVCs and
282 described uncertainty as to when they were '*accredited*' inserters. However, it was noted that a
283 patient deemed difficult for one HCP may not be difficult for another HCP. While some
284 participants reported PIVCs were inserted by both nurses and doctors, many described a
285 perceived reluctance of doctors to escalate PIVC insertion to more experienced nurses.
286 Interestingly some nursing participants worried about whether it fell within their '*scope of*
287 *practice*'. Staff turnover was also highlighted as an important factor in workforce training
288 considerations with one participant noting '*medical staff frequently rotate or move on*' whilst
289 '*nurses generally stay*'. HCPs in regional, rural and remote settings discussed the ongoing

290 challenges associated with insufficient resources to identify and escalate patients with DIVA,
291 stating *'in the bush just have a go as we have no choice'*. Participants discussed the need to
292 *'provide evidence to decision makers to acquire funding for a DIVA service'* and continued drive
293 to establish *'a vascular access team with sufficient resources'*. However, this change to
294 workforce was believed to be hindered by insufficient resources, and ongoing deficits in
295 education, training and policy and equipment.

296
297 HCPs described a lack of formal PIVC insertion training, regulated accreditation and ongoing
298 skill building particularly in terms of technology-assisted capabilities such as US. *'ICUs seem to
299 have their own rules and they don't actually require us to have - they don't actually regulate that
300 you've passed the accreditation process before placing cannulas'* [MI10A]. HCPs also described
301 the *'benefit of US'* for PIVC insertion in patients with DIVA, however due to a lack of policy
302 and resources, US was not used as often as it should, US machines *'are not readily available'*.
303 Overall HCPs reported a need for more formal PIVC insertion courses suggesting *'more
304 training, cannula options and US'* equipment was needed to enable a skilled workforce. Funding
305 and access to resources was also highlighted as a challenge to implementing US for DIVA, with
306 one participant noting *'US ranks low on priority list for small, underfunded healthcare services'*.
307 Interestingly, experienced inserters described difficulty finding a balance *'between (IV insertion)
308 training and patient care'* [MI7A]. The lack of education and support was particularly evident
309 for medical inserters with participants noting *'nurses, they go to a formal education program'*
310 [RI2A] with such a program lacking for medical staff who relied on on-the-job training using a
311 see-one/do-one approach.

312
313 **Theme 4: Paving the way forward – *'measures need to be in place to prevent failed insertion
314 attempts'***

315 HCPs explained that increased advocacy and processes are needed to protect patients with
316 DIVA. A multi-pronged approach was discussed including improved systems and DIVA
317 identification process. HCPs discussed the need for a flagging system such as '*DIVA alert*
318 *system*' which triggered a clinical pathway including '*improved accessibility to US*'. This would
319 involve having appropriate infrastructure such as US equipment, training, and governance.
320 Some HCPs discussed models of standardised US use for DIVA within discreet departments
321 such as ICU, Emergency Departments or Neonatal ICU. In describing the model of care in place
322 they highlighted some key principles that resulted in success. These included strong leadership
323 that committed over years to training and competence, PIVC policy adherence; early patient
324 assessment and DIVA identification; consideration of the requirement for PIVC and easy access
325 to a well-maintained ultrasound.

326

327 HCPs also reported improved levels of support were needed at the policy level to support
328 individual clinicians provide optimal vascular access care across their shift and health settings.
329 Interestingly, shared decision making was highlighted by HCPs as important strategy to
330 highlight in future DIVA policies, with one HCP stating '*staff should have discussions with*
331 *patients*'. Finally, HCPs discussed '*better preparation*' as important when considering and
332 protecting the patient's long term vessel health and preservation.

333

334 **Interview themes mapped to COM-B sources of behaviour**

335 Interview themes and sub-themes were mapped against the COM-B sources of behaviour and
336 intervention functions to inform potential strategies for future DIVA resource implementation
337 (29) (Table 2).

338 At the policy level, improved DIVA resources are needed with potential expansion of nursing
339 roles, which in turn will increase workforce capability and motivation (10). US education and

340 training will be key and addresses both physical and social opportunity thus increasing
341 motivation, with training increasing both autonomic and reflexive motivation. Educational
342 strategies could include point of care resources such as short videos and example scenarios and
343 training with clear and succinct processes for initial and on-going accreditation.
344 ➤ [Insert Table 3. Interview themes mapped to COM-B sources of behaviour](#)

Table 3. Interview themes mapped to COM-B sources of behaviour

Themes	Sub-themes	COM-B sources of behaviour (in bold) and Intervention functions (Michie et al, 2011)	Multi-component intervention
1 The harmful patient experience persists, with consumer insights not leveraged to effect change	Feeling invisible	Capability (psychological) Education, training, enablement	Education of staff Education and training of inserters Education of patients
	Risk and anticipation of failed PIVC Attempts	Opportunity (social) Restriction, environmental restructuring, enablement	DIVA identification (e-health record)
	Inflexible processes which don't consider patients' needs	Opportunity (physical) Restriction, environmental restructuring, enablement	
2 'Escalation' is just a word on the front lines	Providing day-to-day care for DIVA patients	Motivation (reflective) Education, persuasion, incentivisation, coercion	Education of staff Audit of insertion success per ward
	Reliance on "have a go" culture	Motivation (reflective) Education, persuasion, incentivisation, coercion	Education of staff Audit of insertion success per ward
	Forced to inset PIVCs in an environment lacking resources and support	Opportunity (physical) Restriction, environmental restructuring, enablement	DIVA standard of care and guidelines

3	Heightened risk of insertion failure without resources and training	Awareness of the benefit of a DIVA pathway	Motivation (reflective) Education, persuasion, incentivisation, coercion	Education of staff Audit of insertion success per ward
	Education and equipment to support a skilled workforce	Capability (psychological) Education, training, enablement Opportunity (physical) Restriction, environmental restructuring, enablement	Education of staff Bedside US equipment etc	
	Inserter role and accreditation clarity	Opportunity (physical) Restriction, environmental restructuring, enablement	Initial and ongoing competency Accreditation	
4	Paving the way forward – ‘measures need to be in place to prevent failed insertion attempts	System approach including protocols	Capability (psychological) (physical) Education, training, enablement	Point-of-care resources and tools – evidence-based DIVA assessment and pathway tool; videos, example scenarios
	DIVA identification processes	Capability (psychological) Education, training, enablement Capability (physical) Training, enablement Opportunity (physical) Restriction, environmental restructuring, enablement	Simulation training sessions and clinical skills assessment Peer training models DIVA standard of care and guidelines Evidence-based DIVA assessment and pathway tool	

DIVA = Difficult intravenous access; PIVC = Peripheral intravenous catheter

DISCUSSION

This study achieved its aim to describe the experiences of HCPs and patients regarding DIVA. Our findings suggest that obtaining peripheral vascular access in patients with DIVA is an ongoing clinical issue spanning multiple healthcare settings, with patients often feeling unsupported and invisible. However, HCPs caring for patients with DIVA reported feeling restricted in their abilities to provide care owing to an absence of DIVA policies, resource shortages (US machines) and insufficient trained staff across the 24-hour shift. Across all themes, HCPs expressed anxiety stemming from the consequences of failed PIVC insertions, including pain, trauma, delayed treatment. Concern about obtaining PIVC access in patients with DIVA, exacerbated the workforce's existing vulnerabilities and clinical resource challenges, further impacting clinicians' confidence to provide care. Our findings suggest that the current clinical landscape for DIVA remains largely unchanged since previous international reports (15) with the healthcare system failing to leverage important insights to effect change and improve care.

Another key finding was that, across all healthcare settings the 'have a go' attitude persists. Many HCPs in metropolitan facilities spoke about their facility being a training facility, with limited support to identify or escalate DIVAs and the existence of an unspoken understanding that junior medical staff or ward nurses made the first attempt/s before calling for assistance. This finding may reflect uncertainty with respect to guidelines for DIVA and human resource constraints but may also be reflective of historic medical practices. Further PIVC insertion, or failed insertion is not viewed by the health system as having serious negative outcomes (38, 49-51). Overcoming a traditional and ingrained ethos requires consideration of influencing contextual factors and resource limitations. In rural and remote settings, the current practice of 'just have a go' is particularly endemic due to limited skill mix, the wide scope of health staff (particularly nurses), lack of education and support, and the nature of being self-reliant (52, 53). Escalation pathways for DIVA patients in rural and remote settings would need

to educate the most stable and plentiful element of the workforce: nurses. This was a challenge identified in this study due to two reasons: firstly, within the political hierarchy it was not accepted that the nurse should be the escalation point over medical staff; and, secondly, most rural and remote workforces lack stability and have frequent turnover (across disciplines). However, for this type of practice to be changed, support from organisational structure must be evident before clinical change can occur (54). Further, technology support for distance education in the context of US for DIVA training is complicated by poor internet connectivity and bandwidth and a lack of access to US machines (55).

Some of the trade-offs geographically isolated patients reported to manage their DIVA were akin to those faced by metropolitan patients. However, a number were unique and complicated by geographic isolation and the resource poor environments. These differences led to extreme coping strategies such as self-cannulation or treatment discontinuation. The consequences of being unable to gain PIVC in these settings include facility transfer (56), or to escalation to Intraosseous access (57). Further, if US equipment was available, it was likely staff were not trained in its use due to education deficits and/or staff turnover. Our findings show patients with DIVA, living in rural and remote areas, feel more vulnerable compared to metropolitan counterparts, and with a perception of limited resources to support PIVC insertion. This experience was mirrored in a systematic review of chronic disease and healthcare access which identified the common elements of *geography* (having to travel long distances to access care), *availability of health professionals* (rural areas lacking staff with specialist skills, or being caught in referral ‘games’ between metropolitan and rural/remote staff), and *rural culture* (feeling like outsiders in metropolitan environments, wanting to be self-sufficient) (58) as having a negative impact on the patient experience.

A multifaceted approach is needed to develop a solution to the challenges described in this study. Both patient and HCP participants identified a solution would involve several

strategies including: DIVA pathways, escalation policies, US-guided PIVC insertion training and accreditation. Overall, the development of DIVA health policy was viewed as essential.

Additionally, it is timely to commence discussions of possible versus best practice for those in rural and remote contexts. Due to lack of resources (e.g., stable staffing, wider scope of practice for staff, ability to maintain training requirements with the other mandated training, and physical resources of US machine availability), and processes to manage escalation and consequences of not being able to manage escalations locally need to be considered when developing local policy. The results of this study can be used to inform the development of national DIVA US pathways and associated implementation strategies. However, we have identified several important factors which would impact its successful implementation, such as higher staff turnover in rural and remote settings compared to metropolitan areas (59). If this is applied to the education approach to manage access to US-guided PIVC then current studies showing a turnover rate of 148% in nursing staff and 80% in Aboriginal health practitioners (60) would negate the ability to service the educational needs of staff in rural and remote settings.

The ultimate impact of a DIVA VA pathway and US uptake depends not only on its effectiveness but also on its reach and uptake in the health system and the extent to which it is implemented with high levels of completeness (61). A unique finding of our study was the preliminary implementation mapping against The behaviour Change Wheel or COM-B (29) using the interview themes and sub-themes is a systematic framework for identifying multi-faceted strategies to achieve behaviour change that is hopefully sustained overtime. This information can be used in future to develop a logic model to describe the causes and effects (shared relationships including resources, activities, and outputs) of a DIVA pathway incorporating great use of US implementation on desired clinical endpoints. This preliminary mapping provides a systematic process for developing strategies to improve the adoption, implementation and maintenance of a DIVA pathway in healthcare.

–

Our findings may not be generalizable to all health services due to the qualitative nature of the investigation and potential selection bias. However, we adopted a wide, inclusive sampling technique to capture a broad participant group to enhance transferability of findings (62) across the Australian healthcare setting, however this may not be applicable to international health contexts.

CONCLUSION

The findings of this study highlight DIVA patients continue to have a poor healthcare experience in the context of PIVC insertion. Poor standardisation of DIVA assessment, escalation, US use and clinician education across hospitals has contributed to the current rates of dissatisfaction with DIVA services. US-guided insertion of PIVCs is recommended by international guidelines for DIVA patients, and would likely improve the DIVA experience, but uptake in Australia has been sporadic with limited resources and infrastructure to support its ongoing use. Quality and safety improvement opportunities exist to improve the patient with DIVA experience and prevent traumatic insertions. These opportunities primarily situate around the development of new health policy related to DIVA. Further, understanding the barriers and facilitators, particularly from rural and regional health settings, is important for informing future DIVA strategies in these complex populations.

ACKNOWLEDGMENTS

We would like to acknowledge the consumers and clinicians who willingly gave of their time to participate in this study. We would also like to thank Rita Nemeth for help with preparing the manuscript for submission.

REFERENCES

1. Chen S, O'Malley M, Chopra V. How common are indwelling devices in hospitalized adults? A contemporary point prevalence study in a tertiary care hospital. *Am J Infect Control*. 2020.
2. Larsen P, Eldridge D, Brinkley J, Newton D, Goff D, Hartzog T, et al. Pediatric peripheral intravenous access: does nursing experience and competence really make a difference? *J Infus Nurs*. 2010;33(4):226-35.
3. Legemaat M, Carr PJ, van Rens RM, van Dijk M, Poslawsky IE, van den Hoogen A. Peripheral intravenous cannulation: complication rates in the neonatal population: a multicenter observational study. *J Vasc Access*. 2016;17(4):360-5.
4. Peterson KA, Phillips AL, Truemper E, Agrawal S. Does the use of an assistive device by nurses impact peripheral intravenous catheter insertion success in children? *J Pediatr Nurs*. 2012;27(2):134-43.
5. Reigart JR, Chamberlain KH, Eldridge D, O'Brien ES, Freeland KD, Larsen P, et al. Peripheral intravenous access in pediatric inpatients. *Clin Pediatr (Phila)*. 2012;51(5):468-72.
6. Witting MD. IV access difficulty: incidence and delays in an urban emergency department. *J Emerg Med*. 2012;42(4):483-7.
7. Whalen M, Maliszewski B, Baptiste DL. Establishing a Dedicated Difficult Vascular Access Team in the Emergency Department: A Needs Assessment. *J Infus Nurs*. 2017;40(3):149-54.
8. Ehrhardt BS, Givens KEA, Lee RC. Making It Stick: Developing and Testing the Difficult Intravenous Access (DIVA) Tool. *Am J Nurs*. 2018;118(7):56-62.
9. August D, Ullman AJ, Rickard CM, New K. Peripheral intravenous catheter practices in Australian and New Zealand neonatal units: A cross-sectional survey. *Journal of Neonatal Nursing*. 2019;25(5):240-4.
10. Sou V, McManus C, Mifflin N, Frost SA, Ale J, Alexandrou E. A clinical pathway for the management of difficult venous access. *BMC Nurs*. 2017;16:64.
11. Sebbane M, Claret P-G, Lefebvre S, Mercier G, Rubenovitch J, Jreige R, et al. Predicting Peripheral Venous Access Difficulty in the Emergency Department Using Body Mass Index and a Clinical Evaluation of Venous Accessibility. *The Journal of Emergency Medicine*. 2013;44(2):299-305.
12. Paliadelis PS, Parmenter G, Parker V, Giles M, Higgins I. The challenges confronting clinicians in rural acute care settings: a participatory research project. *Rural Remote Health*. 2012;12:2017.
13. van Loon FH, Leggett T, Bouwman AR, Dierick-van Daele AT. Cost-utilization of peripheral intravenous cannulation in hospitalized adults: An observational study. *J Vasc Access*. 2020:1129729820901653.
14. Marsh N, Webster J, Larsen E, Genzel J, Cooke M, Mihala G, et al. Expert versus generalist inserters for peripheral intravenous catheter insertion: a pilot randomised controlled trial. *Trials*. 2018;19(1):564.
15. Cooke M, Ullman AJ, Ray-Barruel G, Wallis M, Corley A, Rickard CM. Not "just" an intravenous line: Consumer perspectives on peripheral intravenous cannulation (PIVC). An international cross-sectional survey of 25 countries. *PLoS One*. 2018;13(2):e0193436.
16. ACSQHC. Management of Peripheral Intravenous Catheters Clinical Care Standard. Sydney, NSW: Australian Commission on Safety and Quality in Health Care (ACSQHC); 2021. p. 54.

17. Schults J, Rickard C, Kleidon T, Paterson R, Macfarlane F, Ullman A. Difficult Peripheral Venous Access in Children: An International Survey and Critical Appraisal of Assessment Tools and Escalation Pathways. *J Nurs Scholarsh*. 2019;51(5):537-46.
18. Schults JA, Kleidon T, Chopra C, Cooke M, Paterson RS, Ullman AJ, et al. International recommendations for a vascular access minimum data set: A Delphi consensus-building study. *BMJ Safety & Quality*. 2020.
19. Schults JA, Rickard CM, Kleidon T, Hughes R, Macfarlane F, Hung J, et al. Building a Global, Pediatric Vascular Access Registry: A Scoping Review of Trial Outcomes and Quality Indicators to Inform Evidence-Based Practice. *Worldviews Evid Based Nurs*. 2019.
20. Schults JA, Woods C, Cooke M, Kleidon T, Marsh N, Ray-Barruel G, et al. Healthcare practitioner perspectives and experiences regarding vascular access device data: An exploratory study. *International Journal of Healthcare Management*. 2020:1-8.
21. Paterson RS, Chopra V, Brown E, Kleidon TM, Cooke M, Rickard CM, et al. Selection and Insertion of Vascular Access Devices in Pediatrics: A Systematic Review. *Pediatrics*. 2020;145(Suppl 3):S243-S68.
22. Chopra V, Flanders SA, Saint S, Woller SC, O'Grady NP, Safdar N, et al. The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. *Ann Intern Med*. 2015;163(6 Suppl):S1-40.
23. Stolz LA, Cappa AR, Minckler MR, Stolz U, Wyatt RG, Binger CW, et al. Prospective evaluation of the learning curve for ultrasound-guided peripheral intravenous catheter placement. *J Vasc Access*. 2016;17(4):366-70.
24. Archer-Jones A, Snelling PJ, Watkins S. Establishing a hospital-based ultrasound-guided peripheral intravenous catheter training programme: A narrative of a 5-year experience. *Emerg Med Australas*. 2020;32(6):1080-3.
25. Alexandrou E, Ray-Barruel G, Carr PJ, Frost SA, Inwood S, Lin F, et al. Peripheral intravenous catheters: an international, cross-sectional study *J Hosp Med*. 2018;13(5):doi: 10.12788/jhm.3039.
26. van Loon FHJ, Buise MP, Claassen JJF, Dierick-van Daele ATM, Bouwman ARA. Comparison of ultrasound guidance with palpation and direct visualisation for peripheral vein cannulation in adult patients: a systematic review and meta-analysis. *Br J Anaesth*. 2018;121(2):358-66.
27. Bodenham Chair A, Babu S, Bennett J, Binks R, Fee P, Fox B, et al. Association of Anaesthetists of Great Britain and Ireland: Safe vascular access 2016. *Anaesthesia*. 2016;71(5):573-85.
28. Alexandrou E, Ray-Barruel G, Carr PJ, Frost SA, Inwood S, Higgins N, et al. Use of Short Peripheral Intravenous Catheters: Characteristics, Management, and Outcomes Worldwide. *J Hosp Med*. 2018;13(5).
29. Michie S, Ashford S, Sniehotta FF, Dombrowski SU, Bishop A, French DP. A refined taxonomy of behaviour change techniques to help people change their physical activity and healthy eating behaviours: the CALO-RE taxonomy. *Psychol Health*. 2011;26(11):1479-98.
30. Larsen E, Keogh S, Marsh N, Rickard C. Experiences of peripheral IV insertion in hospital: a qualitative study. *Br J Nurs*. 2017;26(19):S18-S25.
31. Sandelowski M. What's in a name? Qualitative description revisited. *Res Nurs Health*. 2010;33(1):77-84.
32. Krein SL, Harrod M, Weston LE, Garlick BR, Quinn M, Fletcher KE, et al. Comparing peripherally inserted central catheter-related practices across hospitals with different

insertion models: a multisite qualitative study. *BMJ Quality & Safety*. 2020;bmjqs-2020-011987.

33. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349-57.
34. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. *Adm Policy Ment Health*. 2015;42(5):533-44.
35. Fincham JE. Response rates and responsiveness for surveys, standards, and the Journal. *Am J Pharm Educ*. 2008;72(2):43-.
36. Archer-Jones A, Sweeny A, Schults JA, Rickard CM, Johnson L, Gunter A, et al. Evaluating an ultrasound-guided peripheral intravenous cannulation training program for emergency clinicians: An Australian perspective. *Australas Emerg Care*. 2020;23(3):151-6.
37. Heinrichs J, Fritze Z, Klassen T, Curtis S. A systematic review and meta-analysis of new interventions for peripheral intravenous cannulation of children. *Pediatr Emerg Care*. 2013;29(7):858-66.
38. Marsh N, Webster J, Larsen E, Genzel J, Cooke M, Mihala G, et al. Expert versus generalist inserters for peripheral intravenous catheter insertion: a pilot randomised controlled trial. *Trials*. 2018;19(1):564-.
39. Marsh N, Webster J, Larson E, Cooke M, Mihala G, Rickard CM. Observational Study of Peripheral Intravenous Catheter Outcomes in Adult Hospitalized Patients: A Multivariable Analysis of Peripheral Intravenous Catheter Failure. *J Hosp Med*. 2018;13(2):83-9.
40. Kleidon TM, Cattanach P, Mihala G, Ullman AJ. Implementation of a paediatric peripheral intravenous catheter care bundle: A quality improvement initiative. *J Paediatr Child Health*. 2019;0(0).
41. Creswell JW. *Qualitative inquiry and research design: Choosing among five approaches*. Thousand Oaks, CA: SAGE; 2007.
42. Seale C, Silverman D. Ensuring rigour in qualitative research. *Eur J Public Health*. 1997;7(4):379-84.
43. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough? *Field Methods*. 2016;18(1):59-82.
44. Norwood SL. *Research essentials: Foundations for evidence-based practice*: Prentice Hall; 2010.
45. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3(2):77-101.
46. Koch T. Establishing rigour in qualitative research: the decision trail. *J Adv Nurs*. 2006;53(1):91-100.
47. Norwood SL. *Research Essential: Foundations for Evidence-Based Practice*. New Jersey: Pearson; 2010.
48. Lincoln YS, Guba EG. But is it rigorous? Trustworthiness and authenticity in naturalistic evaluation. *New Directions for Program Evaluation*. 1986;1986(30):73-84.
49. Robertson K. The role of the I.V. Specialist in Health Care Reform. *J Intraven Nurs*. 1995;18(3):130-44.
50. Marsh N, Larsen E, Webster J, Cooke C, Rickard C. The benefit of a vascular access specialist placing a peripheral intravenous catheter: a narrative review of the literature. *Vascular Access*. 2020;6(1):10-5.

51. Marsh N, Larsen L, Hewer B, Monteagle E, Ware R, Schults J, et al. 'How many audits do you really need?': Learnings from 5-years of Peripheral Intravenous Catheter Audits. *Infect Dis Health*. 2021.
52. Calleja P, Adonteng-Kissi B, Romero B. Transition support for new graduate nurses to rural and remote practice: A scoping review. *Nurse Educ Today*. 2019;76:8-20.
53. Burrows GL, Calleja P, Cooke M. What are the support needs of nurses providing emergency care in rural settings as reported in the literature? A scoping review. *Rural Remote Health*. 2019;19(2):4805.
54. Moran AM, Coyle J, Pope R, Boxall D, Nancarrow SA, Young J. Supervision, support and mentoring interventions for health practitioners in rural and remote contexts: an integrative review and thematic synthesis of the literature to identify mechanisms for successful outcomes. *Hum Resour Health*. 2014;12:10.
55. Ashley C, Halcomb E, Brown A, Peters K. Experiences of registered nurses transitioning from employment in acute care to primary health care-quantitative findings from a mixed-methods study. *J Clin Nurs*. 2018;27(1-2):355-62.
56. Morgan JM, Calleja P. Emergency trauma care in rural and remote settings: Challenges and patient outcomes. *Int Emerg Nurs*. 2020;51:100880.
57. Howarth D. Adult intraosseous access - experiences in a remote emergency department. *Aust Fam Physician*. 2011;40(7):510-1.
58. Brundisini F, Giacomini M, DeJean D, Vanstone M, Winsor S, Smith A. Chronic disease patients' experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis. *Ont Health Technol Assess Ser*. 2013;13(15):1-33.
59. Russell DJ, Zhao Y, Guthridge S, Ramjan M, Jones MP, Humphreys JS, et al. Patterns of resident health workforce turnover and retention in remote communities of the Northern Territory of Australia, 2013-2015. *Human resources for health*. 2017;15(1):52-.
60. Wakerman J, Humphreys J, Russell D, Guthridge S, Bourke L, Dunbar T, et al. Remote health workforce turnover and retention: what are the policy and practice priorities? *Human Resources for Health*. 2019;17(1):99.
61. Fernandez ME, Ten Hoor GA, van Lieshout S, Rodriguez SA, Beidas RS, Parcel G, et al. Implementation Mapping: Using Intervention Mapping to Develop Implementation Strategies. *Front Public Health*. 2019;7:158-.
62. Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research*. Thousand Oaks, CA: SAGE; 2018.